Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases

[1]  D. Rimm,et al.  Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.

[2]  M. D. Di Marino,et al.  Neuroendocrine differentiation in non-small cell lung carcinomas. , 2000, In vivo.

[3]  G. Pelosi,et al.  Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma , 2003, Cancer.

[4]  Jacques Ferlay,et al.  Cancer incidence in five continents. , 1976, IARC scientific publications.

[5]  S. Cha,et al.  Neuroendocrine differentiation is an independent prognostic factor in chemotherapy‐treated nonsmall cell lung carcinoma , 1996, Cancer.

[6]  R. Wood‐Baker,et al.  Nonsmall Cell Lung Carcinoma With Neuroendocrine Differentiation—An Entity of No Clinical or Prognostic Significance , 2007, The American journal of surgical pathology.

[7]  Y. Haga,et al.  Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung. , 2002, The Annals of thoracic surgery.

[8]  Elisabeth Brambilla,et al.  Pathology and genetics of tumours of the lung , pleura, thymus and heart , 2004 .

[9]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Kerr,et al.  Neuroendocrine differentiation in non‐small cell lung cancer and its relation to prognosis and therapy , 2005, Histopathology.

[11]  Armando Santoro,et al.  Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  L. Fabbri,et al.  Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Baskić,et al.  Neuron specific enolase tissue expression as a prognostic factor in advanced non small cell lung cancer. , 2008, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[14]  R. Greil,et al.  [Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms]. , 2007, Wiener klinische Wochenschrift.

[15]  A. Gajra,et al.  The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer. , 2002, Lung cancer.

[16]  J. Carles,et al.  Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. , 1993, Lung cancer.

[17]  S. Takashima,et al.  Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications , 2009, Journal of Cancer Research and Clinical Oncology.

[18]  Martin W. Bunder,et al.  The inconsistency of , 1976, Journal of Symbolic Logic.

[19]  L. Fabbri,et al.  Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFRα, PDGFRβ, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung , 2005 .

[20]  S. Störkel,et al.  Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[21]  N. Perkins,et al.  The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. , 2006, American journal of epidemiology.

[22]  A. Marchevsky,et al.  Morphometry confirms the presence of considerable nuclear size overlap between "small cells" and "large cells" in high-grade pulmonary neuroendocrine neoplasms. , 2001, American journal of clinical pathology.

[23]  F. Levi,et al.  Cancer incidence in five continents, vol. VI , 1993 .

[24]  Alexandar Tzankov,et al.  Tissue microarray technology: principles, pitfalls and perspectives—lessons learned from hematological malignancies , 2005, Experimental Gerontology.

[25]  R. Greil,et al.  Twelve-year retrospective analysis of lung cancer--The TYROL Study: Daily routine in 1,424 patients (1995-2006) , 2008 .

[26]  Kenji Suzuki,et al.  Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. , 2002, The Journal of thoracic and cardiovascular surgery.

[27]  F. Ploner,et al.  Expertenempfehlung 2006 zur rationalen Zweitlinien-Therapie beim nicht-kleinzelligen Bronchuskarzinom , 2007, Wiener klinische Wochenschrift.

[28]  J. Mortimer,et al.  The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.